SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial) (SIKAMIC)

  • End date
    Jun 9, 2023
  • participants needed
  • sponsor
Updated on 9 April 2022


The purpose of this phase IIb, international, multicentre, double-blind, randomised, placebo-controlled study is to determine the effect of hydroxycarbamide on albuminuria after 6 months of treatment in SCD adult patients.

Condition Sickle Cell Disease
Treatment Placebo Oral Tablet, Hydroxycarbamide, Hydroxycarbamide
Clinical Study IdentifierNCT03806452
Last Modified on9 April 2022


Yes No Not Sure

Inclusion Criteria

Signed and dated Informed Consent Form (ICF) by a legally competent patient
Patients above 18 years
Patients with HbSS or HbSβ0 SCD
Patients with a value of albuminuria, assessed by ACR, over 3 mg/mmol and inferior to 100 mg/mmol confirmed by 3 positive urine samples taken one day apart
Female patients of childbearing potential or postmenopausal female with last period < 12 months before screening agreeing to use a highly effective form of contraception (oral, injected or implanted hormonal contraception, intrauterine device, diaphragm, condom) during the trial and for 3 months after hydroxycarbamide discontinuation
Male patients with partners of childbearing potential agreeing to use a highly effective contraception during the trial and for 3 months after hydroxycarbamide discontinuation. Men with pregnant or lactating women should be advised to use a barrier method of contraception (condom) to prevent the foetus or breastfed infant from exposure to hydroxycarbamide
Patients who are covered by insurance scheme according to local regulatory requierements

Exclusion Criteria

Patients who had severe VOC requiring hospitalisation or ACS within the last 4 weeks preceding screening visit
Patients treated with hydroxycarbamide for any reason within the previous 6 months
Patients who have had chronic blood transfusion or transfusion in the last 3 months
Patients with a history of hypertension (systolic blood pressure ≥ 140 or diastolic blood pressure ≥ 90 mmHg) treated with antihypertensive agent belonging to pharmacological class of RAS inhibitor
Patients who have symptoms suggestive of urinary tract infection or patients with gross haematuria
Patients with a concomitant primary kidney disease
Patients with any systemic condition that could result in a glomerulopathy not related to SCD (e.g. diabetes mellitus, active hepatitis B or C infections, HIV infection, systemic lupus erythematosus, inflammatory arthropathies)
Patient with a stage 3, 4 or 5 chronic kidney disease (eGFR < 60 mL/min per 1.73 m2)
Patients with eGFR ≥ 140 ml/min/1,73m² due to the lack of information regarding the magnitude, direction and significance of the trends in eGFR evolution that could be expected in this population
Patients requiring long-term treatment with drugs potentially nephrotoxic (see non-exhaustive list)
Patients requiring ACE inhibitors or ARBs within the 3 months before inclusion regardless of the indication
Patients requiring long-term treatment with non-steroid anti-inflammatory drugs
Patients who have a treatment which can modify the kidney function (see non-exhaustive list) in the last 3 months
Patients known to be infected with HIV
Female patients who are pregnant or lactating
Unreliable patients including non-compliant patients, patients with known alcoholism or drug abuse or with a history of a serious psychiatric disorder as well as patients unwilling to give informed consent or to abide by the requirements of the protocol
Simultaneous participation in other clinical trials on an investigational medicinal product or previous participation within 30 days before inclusion
Persons in detention by judicial or administrative decision
Patients with chronic conditions that upon investigator judgment may lead to a limited life expectancy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note